Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued to investors on Wednesday,RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s target price indicates a potential upside of 384.58% from the company’s previous close.

Several other equities research analysts have also recently commented on CATX. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Price Performance

NYSE CATX traded down $0.20 during mid-day trading on Wednesday, reaching $2.27. 738,740 shares of the stock were exchanged, compared to its average volume of 991,089. Perspective Therapeutics has a one year low of $2.22 and a one year high of $19.05. The stock has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $6.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CATX. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics in the 4th quarter valued at $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $34,000. National Bank of Canada FI lifted its position in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics in the 4th quarter worth about $51,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.